Glenmark Pharmaceuticals ltd — Capital/Financing Update 2024

Jul 10, 2024

==> picture [16 x 10] intentionally omitted <==

==> picture [18 x 11] intentionally omitted <==

==> picture [149 x 45] intentionally omitted <==

July 10, 2024

To, Dy. General Manager Department of Corporate Services, BSE Ltd. Phiroze Jeejeebhoy Towers Dalal Street, Fort, Mumbai – 400 001

Ref: Scrip Code: 532296

To, The Manager – Listing National Stock Exchange of India Ltd., Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051

Ref: Scrip Name: GLENMARK

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

We wish to inform you that the Board of Directors, at its meeting held today on July 10, 2024, approved the sale of up to 96,09,571 equity shares of Glenmark Life Sciences Limited (“ GLS ”) representing 7.84% of the issued and paid‐up equity share capital of GLS, held by the Company (including equity shares held by certain individuals where the beneficial ownership is with the Company), by way of an offer for sale through the stock exchange mechanism, in accordance with the applicable law.

This is for your information and records.

For and on behalf of Glenmark Pharmaceuticals Limited

HARISH Digitally signed by HARISH VINAYA VINAYAK KUBER Date: 2024.07.10 K KUBER 15:38:48 +05'30'

Harish Kuber Company Secretary and Compliance Officer Tel: 4018 9999 / 4018 9879 Fax: 4018 9986 (Legal & Secretarial Dept.)

Glenmark Pharmaceuticals Ltd. Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099 T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com